Eva M. Murauer
Salzburg, 5020, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
A guide to effective drug development through nonprofit models.
Journal: Nature reviews. Drug discovery
Published: May 28, 2026
Response to 'Non-profits wade in where for-profit life science investment fears to tread'.
Journal: Nature biotechnology
Published: January 19, 2026
Philanthropic drug development: understanding its importance, mechanisms, and future prospects.
Journal: Drug discovery today
Published: November 13, 2024
COL7A1 Editing via RNA Trans-Splicing in RDEB-Derived Skin Equivalents.
Journal: International journal of molecular sciences
Published: December 21, 2022
5'RNA Trans-Splicing Repair of COL7A1 Mutant Transcripts in Epidermolysis Bullosa.
Journal: International journal of molecular sciences
Published: November 15, 2021
QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study.
Journal: The Journal of investigative dermatology
Published: November 07, 2019
A cancer stem cell-like phenotype is associated with miR-10b expression in aggressive squamous cell carcinomas.
Journal: Cell communication and signaling : CCS
Published: June 30, 2019
RNA Trans-Splicing Modulation via Antisense Molecule Interference.
Journal: International journal of molecular sciences
Published: January 30, 2018
Functional therapies for cutaneous wound repair in epidermolysis bullosa.
Journal: Advanced drug delivery reviews
Published: July 20, 2017
Cut and Paste: Efficient Homology-Directed Repair of a Dominant Negative KRT14 Mutation via CRISPR/Cas9 Nickases.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: May 18, 2017
An RNA-targeted therapy for dystrophic epidermolysis bullosa.
Journal: Nucleic acids research
Published: May 11, 2017
Last Updated: 09/26/2026